NASDAQ:TYME
Delisted

Tyme Technologies Stock Signals

etoro logo Buy TYME
*Your capital is at risk
$0.311
+0 (+0%)
At Close: Jan 27, 2023

Latest Data & Signals Issued

Below are some of the latest signals issued for Tyme Technologies Inc

General

Signal Type Signal Value Data
Score 0.000 92 days ( 0 %
Last Price $0.311 0 %
Performance History
7 Days
$0.311 $0.311
0%
30 Days
$0.311 $0.311
0%
12 Mos
$0.361 $0.311
-13.93%

4/18

Active Buy Signals

Specific Signals

Short Term
Net score: 15.54
Signal Type Signal Value Importance Data
High / Low N/A Very Low $0.311 - $0.311
Trend - 3 mos 0 % High Width: 0 %
Pred. range - 3 mos N/A - N/A Low -100.00 % - -100.00 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Jan 26, 2023 - 2 days
RSI Short Pivot Signal Sell Very Low Nov 30, -0001 - N/A days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 54.33
Signal Type Signal Value Importance Data
Trend - 12 mos -2.87 % Very High Width: 65.83 %
Pred. range - 12 mos $0.213 - $0.354 High -31.32 % - 13.89 %
Short MA 12 mos Buy Very High Sep 12, 2022 - 96 days
Long MA 12 mos Buy Very High Sep 14, 2022 - 94 days
Short/Long MA 12 mos Buy Very High Sep 22, 2022 - 88 days
Pivot Long Sell Low Jan 26, 2023 - 2 days
RSI Long Pivot Signal Sell Low Oct 10, 2022 - 76 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT TYME TECHNOLOGIES INC
Tyme Technologies
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the ...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
7.87% Jun 12
DHI
$146.71
3.93% Jun 10
PHM
$118.49
2.86% Jun 10
EAT
$140.46
13.06% Jun 05
TPR
$140.47
3.84% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE